Chargement en cours...
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registr...
Enregistré dans:
| Publié dans: | Multidiscip Respir Med |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5950183/ https://ncbi.nlm.nih.gov/pubmed/29785264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0126-7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|